Clinical trialNCT04139304RecruitingEarly phase 1Interventional

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

SponsorAIDS Malignancy ConsortiumEnrollment15Ann Arbor Stage I Diffuse Large B-Cell LymphomaAnn Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell LymphomaPlasmablastic Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-EPOCH) works in treating patients with newly diagnosed stage I-IV plasmablastic lymphoma. Plasmablastic lymphoma cells have high levels of a protein called CD38. Daratumumab is a monoclonal antibody that specifically targets CD38 expressing cells, and may help the body's immune system attack the cancer and interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab may enhance the effectiveness of a standard chemotherapy (DA-EPOCH) in patients with plasmablastic lymphoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Ariela Noy, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Miami Miller School of Medicine
Miami, Florida, United States
Juan C Ramos, MD
Recruiting
University of Illinois at Chicago
Chicago, Illinois, United States
Paul Rubinstein, MD
Recruiting
Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Richard Ambinder, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Ariela Noy, MD
Recruiting
University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States
Christopher Dittus, DO, MPH
Recruiting
the Ohio State University
Columbus, Ohio, United States
Robert Baiocchi, MD, PhD
Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Stefan Barta, MD
Recruiting
the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Raphael Steiner, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cyclophosphamide →Daratumumab →Doxorubicin →Etoposide →Prednisone →Vincristine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 May 2021
Primary completion: 31 Jul 2029
Completion: 31 Jul 2030
Last update posted: 1 Jun 2026
Registered enrollment: 15
Registry id: NCT04139304

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.